U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H13N3O5
Molecular Weight 243.2166
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYTARABINE

SMILES

NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O

InChI

InChIKey=UHDGCWIWMRVCDJ-CCXZUQQUSA-N
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

HIDE SMILES / InChI

Molecular Formula C9H13N3O5
Molecular Weight 243.2166
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
Curator's Comment: Description was created using several sources including: http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28680 http://www.tandfonline.com/doi/abs/10.1517/17425247.2010.527330

Cytarabine is a pyrimidine nucleoside analog. Cytarabine or cytosine arabinoside (Cytosar-U or Depocyt) is a chemotherapy agent used mainly in the treatment of cancers of white blood cells such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma. It also has antiviral and immunosuppressant properties. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It is a cell cycle phase-specific, affecting cells only during the S phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA polymerase. Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.The drug has a short plasma half-life, low stability and limited bioavailability. Overdosing of patients with continuous infusions may lead to side effects. Thus, various prodrug strategies and delivery systems have been explored extensively to enhance the half-life, stability and delivery of cytarabine. Alternative, delivery systems of cytarabine have emerged for the treatment of different cancers. The liposomal-cytarabine formulation has been approved for the treatment of lymphomatous meningitis.

CNS Activity

Originator

Curator's Comment: Cytarabine was first synthesized in 1959 by Richard Walwick, Walden Roberts, and Charles Dekker at the University of California, Berkeley. It was approved by the United States Food and Drug Administration in June 1969, and was initially marketed in the U.S. by Upjohn under the trade name Cytosar-U and is at present manufactured by Pfizer, Sicor Pharmaceuticals and Teva. CYTOSAR (cytarabine injection) was developed in September 1994 Dana-­Farber Cancer Institute and is manufactured by Pfizer and Perrigo. DEPOCYT - (cytarabine injection, lipid complex) manufactured by Manufactured by: Pacira Pharmaceuticals Inc., distributed by Sigma-Tau Pharmaceutical, Inc. is an intrathecal cancer chemotherapeutic agent approved by FDA is used for the treatment of lymphomatous meningitis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
Primary
CYTARABINE

Approved Use

Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine injection (preservative-free only) is indicated for the prophylaxis and treatment of meningeal leukemia.

Launch Date

-1.71072E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
62.2 μg/mL
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1900 μg × h/mL
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
40.4 h
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
80 h
50 mg single, intrathecal
dose: 50 mg
route of administration: Intrathecal
experiment type: SINGLE
co-administered:
CYTARABINE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.363, 366
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.363, 366
Disc. AE: Cerebellar disorder NOS, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Cerebellar disorder NOS (grade 4, 66.7%)
Diarrhea (grade 3, 66.7%)
Sources: Page: p.363, 366
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.2578
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.2578
Disc. AE: Cerebellar disorder NOS, Cerebellar disorder NOS...
AEs leading to
discontinuation/dose reduction:
Cerebellar disorder NOS (grade 4, 33.3%)
Cerebellar disorder NOS (grade 5, 16.7%)
Sources: Page: p.2578
3 g/m2 2 times / day multiple, intravenous
MTD
Dose: 3 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 3 g/m2, 2 times / day
Sources: Page: p.366
unhealthy, 16-76
n = 27
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 27
Sources: Page: p.366
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Disc. AE: Bone marrow depression, Leukopenia...
AEs leading to
discontinuation/dose reduction:
Bone marrow depression
Leukopenia
Thrombocytopenia
Anemia
Nausea
Vomiting
Diarrhea
Abdominal pain
Oral ulceration
Hepatic dysfunction NOS
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Diarrhea grade 3, 66.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.363, 366
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.363, 366
Cerebellar disorder NOS grade 4, 66.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.363, 366
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.363, 366
Cerebellar disorder NOS grade 4, 33.3%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.2578
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.2578
Cerebellar disorder NOS grade 5, 16.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources: Page: p.2578
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources: Page: p.2578
Abdominal pain Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Anemia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Bone marrow depression Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Diarrhea Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Hepatic dysfunction NOS Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Leukopenia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Nausea Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Oral ulceration Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Thrombocytopenia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Vomiting Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 6.6 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Involvement of hydrogen peroxide and hydroxyl radical in chemically induced apoptosis of HL-60 cells.
1999 Jun 15
Pseudotumor cerebri secondary to intermediate-dose cytarabine HCl.
1999 May
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
1999 Nov
Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia.
1999 Sep
Pseudotumor cerebri induced by all-trans-retinoic acid in a child treated for acute promyelocytic leukemia.
2000 Apr
Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1.
2000 Jan-Feb
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
2000 Jul
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
2000 May 1
Acute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols.
2000 Nov
Cerebellar toxicity of cytosine arabinoside: clinical and neuropsychological signs.
2000 Oct 24
Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity.
2000 Sep
Treatment for primary CNS lymphoma: the next step.
2000 Sep
Lenograstim and filgrastim effects on neutrophil motility in patients undergoing chemotherapy: evaluation by computer-assisted image analysis.
2001 Apr
Primary high-grade mucosa-associated lymphoid tissue-type lymphoma of the cervix presenting as a common endocervical polyp.
2001 Apr
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
2001 Apr 1
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
2001 Apr 1
The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses.
2001 Apr 15
Parotid mucoepidermoid carcinoma following chemotherapy for childhood acute lymphoblastic leukemia.
2001 Apr-May
Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia.
2001 Apr-May
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
2001 Feb
Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
2001 Feb 15
[Palpable mantel cell lymphoma in the breast].
2001 Feb 3
Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation.
2001 Jan
[Outcome of acute myelogenous leukemia in 41 patients treated with idarubicin: the prognosis of t(8;21) cases].
2001 Jan
Aseptic meningitis in a child after systemic treatment with high dose cytarabine.
2001 Jan
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.
2001 Jan
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
2001 Jan
Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
2001 Jan
De novo acute myeloid leukemia in the elderly; a consistent fraction of long-term survivors by standard-dose chemotherapy.
2001 Jan
Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis.
2001 Jan
Chemotherapy and marrow transplantation for congenital leukaemia.
2001 Jan
Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
2001 Jan 1
Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment.
2001 Jan 1
Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance.
2001 Jan 1
JP-8 jet fuel-induced DNA damage in H4IIE rat hepatoma cells.
2001 Jan 25
Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside.
2001 Jan-Feb
Therapy of acute myeloid leukemia.
2001 Jan-Feb
Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.
2001 Mar
Neutrophilic eccrine hidradenitis in two neutropaenic patients.
2001 Mar
[All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report].
2001 Mar
Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials.
2001 Mar
Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity?
2001 Mar
Severe hepatic injury associated with lipid formulations of amphotericin B.
2001 Mar 1
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
2001 Mar 15
Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.
2001 Mar 2
Patents

Sample Use Guides

Induction therapy: DepoCyt (cytarabine liposome injection), 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 2 doses (weeks 1 and 3). Consolidation therapy: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13. Maintenance: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 28 days for 4 doses (weeks 17, 21, 25 and 29).
Route of Administration: Intratracheal
In Vitro Use Guide
Curator's Comment: The effect of Ara-C (0.1 μM) treatment on HUVEC proliferation alone or in drug combinations compared to drug-free control cultures. Results are expressed as mean percentage ± SEM from three independent experiments (six replicates per condition) relative to corresponding untreated control cultures.
Human umbilical vein endothelial cells (HUVECs) and human osteosarcoma cell line (Cal72) were incubated with various concentrations of Cytarabine (Ara-C) (0.01–20 μM) for 3 days
Substance Class Chemical
Created
by admin
on Thu Jul 06 22:08:08 UTC 2023
Edited
by admin
on Thu Jul 06 22:08:08 UTC 2023
Record UNII
04079A1RDZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTARABINE
EMA EPAR   EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
CYTARABINE [USP-RS]
Common Name English
CYTARABINE [HSDB]
Common Name English
CYTOSAR-U
Brand Name English
CYTARABINE [EP MONOGRAPH]
Common Name English
CYTARABINE [WHO-IP]
Common Name English
CYTARABINUM [WHO-IP LATIN]
Common Name English
DEPOCYT
Brand Name English
ARACYTIN
Common Name English
U-19,920
Code English
CYTARABINE [USAN]
Common Name English
CYTARABINE LIPOSOME
VANDF  
Common Name English
CYTARABINE [VANDF]
Common Name English
ARACYTIDINE
Common Name English
SPONGOCYTIDINE
Common Name English
CYTARABINE [MI]
Common Name English
ARABINOCYTOSINE
Common Name English
CYTARABINE [ORANGE BOOK]
Common Name English
ARA-C
Common Name English
CYTARABINE LIPOSOME [VANDF]
Common Name English
CYTARABINE [USP IMPURITY]
Common Name English
1-.BETA.-D-ARABINOFURANOSYLCYTOSINE
Common Name English
Cytarabine [WHO-DD]
Common Name English
VYXEOS COMPONENT CYTARABINE
Brand Name English
NSC-287459
Code English
U 19920A
Common Name English
CYTARABINE [MART.]
Common Name English
CYTARABINOSIDE
Common Name English
CYTARABINE [JAN]
Common Name English
U-19920
Code English
ARACYTINE
Common Name English
cytarabine [INN]
Common Name English
CYTARABINE [EMA EPAR]
Common Name English
2(1H)-PYRIMIDINONE, 4-AMINO-1-.BETA.-D-ARABINOFURANOSYL-
Common Name English
CYTARABINE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ATC L01XY01
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
FDA ORPHAN DRUG 234806
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
NDF-RT N0000175595
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
NDF-RT N0000000233
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
EMA ASSESSMENT REPORTS DEPOCYT (AUTHORIZED: MENINGEAL NEOPLASMS)
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
FDA ORPHAN DRUG 265808
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
NCI_THESAURUS C1557
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
FDA ORPHAN DRUG 73393
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
LIVERTOX NBK548291
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
WHO-ATC L01BC01
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
EU-Orphan Drug EU/3/11/942
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
WHO-VATC QL01BC01
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
Code System Code Type Description
RXCUI
968804
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
ALTERNATIVE
ECHA (EC/EINECS)
205-705-9
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
EPA CompTox
DTXSID3022877
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
DRUG BANK
DB00987
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
EVMPD
SUB06880MIG
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
NCI_THESAURUS
C408
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
RXCUI
3041
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
DAILYMED
04079A1RDZ
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
MERCK INDEX
M4051
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY Merck Index
PUBCHEM
6253
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
WIKIPEDIA
CYTARABINE
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
ChEMBL
CHEMBL803
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
RS_ITEM_NUM
1162002
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
FDA UNII
04079A1RDZ
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
IUPHAR
4827
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
DRUG CENTRAL
770
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
CAS
147-94-4
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
MESH
D003561
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
CHEBI
28680
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
SMS_ID
100000089874
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
INN
1709
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
HSDB
3049
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
NSC
287459
Created by admin on Thu Jul 06 22:08:11 UTC 2023 , Edited by admin on Thu Jul 06 22:08:11 UTC 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
kcat
METABOLIC ENZYME -> SUBSTRATE
Km
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
METABOLITE INACTIVE -> PARENT
Produced via Cytidine deaminase exposure.
PLASMA
PRODRUG -> METABOLITE ACTIVE
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
PLASMA
METABOLITE ACTIVE -> PARENT
PLASMA
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC